Impact of surfactants and other body fluids on in vitro activity of a novel β-lactamase inhibitor enmetazobactam in combination with cefepime against clinical isolates of Klebsiella pneumoniae.
Journal
The Journal of antibiotics
ISSN: 1881-1469
Titre abrégé: J Antibiot (Tokyo)
Pays: England
ID NLM: 0151115
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
received:
13
10
2022
accepted:
15
11
2022
revised:
07
11
2022
pubmed:
24
1
2023
medline:
3
3
2023
entrez:
23
1
2023
Statut:
ppublish
Résumé
Surfactants might impact treatment of lower respiratory tract infections. Moreover, other body fluids, such as urine or serum, could impact antibacterial activity as well. Therefore, the impact of surfactants, urine, and serum on the antibacterial activity of the novel β-lactam/β-lactamase inhibitor combination of cefepime-enmetazobactam (FPE) was determined. Ten clinical isolates of Klebsiella pneumoniae, and the quality control strains K. pneumoniae ATCC 700603 and Escherichia coli NCTC 13353, were tested. Minimal Inhibitory Concentration (MIC) determinations (all strains) and Time Kill Curves (TKC) (one clinical isolate) were determined for FPE and piperacillin-tazobactam (TZP) with and without surfactant formulations Survanta® (SUR; 1%v/v) and Curosurf® (CUR; 1 mg ml
Identifiants
pubmed: 36690707
doi: 10.1038/s41429-022-00592-w
pii: 10.1038/s41429-022-00592-w
doi:
Substances chimiques
Cefepime
807PW4VQE3
beta-Lactamase Inhibitors
0
enmetazobactam
80VUN7L00C
Cephalosporins
0
Daptomycin
NWQ5N31VKK
Surface-Active Agents
0
Anti-Bacterial Agents
0
Monobactams
0
beta-Lactamases
EC 3.5.2.6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
183-189Informations de copyright
© 2023. The Author(s), under exclusive licence to the Japan Antibiotics Research Association.
Références
Silverman JA, Mortin LI, VanPraagh ADG, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant: In vitro modeling and clinical impact. J Infect Dis. 2005;191:2149–52.
doi: 10.1086/430352
Gotfried MH, et al. Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics. Antimicrob Agents Chemother. 2008;52:92–97.
doi: 10.1128/AAC.00875-07
Van’t Veen A, Mouton JW, Gommers D, Kluytmans JANAJW, Dekkers P. Influence of pulmonary surfactant on in vitro bactericidal activities of amoxicillin, ceftazidime, and tobramycin. Antimicrob Agents Chemother. 1995;39:329–33.
doi: 10.1128/AAC.39.2.329
Dugourd D, et al. Antimicrobial properties of MX-2401, an expanded-spectrum lipopeptide active in the presence of lung surfactant. Antimicrob Agents Chemother. 2011;55:3720–8.
doi: 10.1128/AAC.00322-11
Schwameis R, et al. Effect of pulmonary surfactant on antimicrobial activity in vitro. Antimicrob Agents Chemother. 2013;57:5151–4.
doi: 10.1128/AAC.00778-13
Nussbaumer-Pröll A, Zeitlinger M. Use of supplemented or human material to simulate pd behavior of antibiotics at the target site in vitro. Pharmaceutics. 2020;12:1–18.
doi: 10.3390/pharmaceutics12080773
Zhanel GG, et al. Ceftolozane/tazobactam: A novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs. 2014;74:31–51.
doi: 10.1007/s40265-013-0168-2
Ian M, Sophie M, Stephen H, Stuart S, Philipp K. In vitro activity of cefepime-enmetazobactam against gram-negative isolates collected from U.S. and European hospitals during 2014–2015. Antimicrob Agents Chemother. 2019;63:1–9.
Papp-wallace KM, et al. Beyond piperacillin-tazobactam: cefepime and AAI101 as a potent β-lactam-β-lactamase inhibitor combination. Antimicrob Agents Chemother. 2019;63:1–17.
doi: 10.1128/AAC.00105-19
Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. (2019). Available at: https://clsi.org/standards/products/iso-documents/iso-20776-12006/ .
Das S, et al. Intrapulmonary pharmacokinetics of cefepime and enmetazobactam in healthy volunteers: Towards new treatments for nosocomial pneumonia. Antimicrob Agents Chemother. 2021;65:e01468-20.
Johnson, A et al. Pharmacodynamics of cefepime combined with the novel extended-spectrum-beta-lactamase (ESBL) inhibitor enmetazobactam for murine pneumonia caused by ESBL-Producing Klebsiella pneumoniae. 2020;64:1–14.
Nussbaumer-Pröll AK, et al. Low pH reduces the activity of ceftolozane / tazobactam in human urine, but confirms current breakpoints for urinary tract infections. J Antimicrob Chemother. 2019;dkz488:1–7.
Castanheira M, Duncan LR, Rhomberg PR, Sader HS. Enhanced activity of cefepime–tazobactam (WCK 4282) against KPC-producing Enterobacteriaceae when tested in media supplemented with human serum or sodium chloride. Diagn Microbiol Infect Dis. 2017;89:305–9.
doi: 10.1016/j.diagmicrobio.2017.08.011